MedTrace Logo

A Study in the US Based on Pharmacy and Medical Claims That Compares How Well Stiolto® and Trelegy® Work in People With Chronic Obstructive Pulmonary Disease (COPD)

NCT05169424 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 9117

Last updated 2023-10-19

Study results available
· View outcomes & findings →

Summary

This study looks at data from people with chronic obstructive pulmonary disease (COPD). Some used Stiolto Respimat and the others Trelegy Ellipta as their first treatment for COPD.

The purpose of this study is to find out how well the treatments worked. Researchers compare the time to first COPD flare-up (exacerbation) between the 2 treatments.

The study analyses anonymous data from pharmacy claims collected over 3.5 years.

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

DEVICE

Trelegy Ellipta

Trelegy Ellipta

DEVICE

Stiolto Respimat

Stiolto Respimat

DRUG

Tiotropium + Olodaterol (5/5 mcg)

Tiotropium + Olodaterol (5/5 mcg)

DRUG

Fluticasone Furoate + Umeclidinium + Vilanterol (100/62.5/25 mcg)

Fluticasone Furoate + Umeclidinium + Vilanterol (100/62.5/25 mcg)

Sponsors & Collaborators

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-17
Primary Completion
2021-12-27
Completion
2021-12-27
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05169424 on ClinicalTrials.gov